Antisense Therapeutics Limited reported earnings results for the half year ended December 31, 2022. For the half year, the company reported sales was AUD 0.171393 million compared to AUD 0.00373 million a year ago. Revenue was AUD 0.493381 million compared to AUD 0.260384 million a year ago.

Net loss was AUD 5.27 million compared to AUD 2.98 million a year ago. Basic loss per share from continuing operations was AUD 0.0079 compared to AUD 0.005 a year ago. Diluted loss per share from continuing operations was AUD 0.0079 compared to AUD 0.005 a year ago.